PTGS2 and colorectal carcinoma: CDH17 expression has been demonstrated in CRC human samples and can be used along with other markers, such as mucin 2 (MUC2) and cyclooxygenase-2 (COX-2), to predict disease progression and prognosis in CRC patients [18,21].